Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
This study has been completed.
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by (Responsible Party):
First received: May 20, 2005
Last updated: April 24, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||July 2005|
|Primary Completion Date:||July 2005 (Final data collection date for primary outcome measure)|
Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol. 2007 Jan;156(1):138-42.